A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

SUMMARY

N/A

COH Protocol Number : 15123

ClinicalTrials.gov Number : NCT02520427

Principal Investigator : Stein, Anthony M.D.

Sponsor : Amgen, Inc.

BRIEF ELIGIBILITY CRITERIA :

Eligible Ages : >=18

Gender : Either

Minimum Performance Status : ECOG/SWOG:2

Treatment Intent : Non-Adjuvant treatment

Prior Chemotherapy :

Brain Metastases :

Measurable Disease :